Slide 1: Exchange cover letter: Investors / Analysts Presentation
July 24, 2026 To To The Corporate Relations Department The Listing Department BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Code: 540222 Code: LAURUSLABS Dear Sir / Madam
Slide 2: Q1-FY 2027 Financial Results
Q1-FY 2027 Financial 20 Years Results logo 24/07/2026 © 2026 Laurus Labs Ltd.
Slide 3: Agenda
Agenda 1 Q1 - FY 2027 Corporate Overview 2 Q1 - FY 2027 Financial Overview 3 Q1 - FY 2027 Business Review & Strategy © 2026 Laurus Labs Ltd. Q1 - FY27 Results Presentation 24/07/2026 2
Slide 4: Safe Harbor Statement
Safe Harbor Statement This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. W
Slide 5: Corporate Overview
1 Corporate Overview Q1 - FY 2027 4
Slide 6: Executive Summary
Executive Summary • Continued strong Q1 performance ; ₹ 2,026 Cr Revenue with 29% growth • Strong growth in CDMO revenue driven by commercial projects supplies and steady momentum in Affordable Medicines segment • ₹ 644 Cr EBITDA with margins of 31.8%, increased by 7.0% pts, contributed by enhanced
Slide 7: Continue to drive Growth CAPEX projects across portfolio and technologies
Continue to drive Growth CAPEX projects across portfolio and technologies Q1 CAPEX : ₹394 Cr FY22-27* CAPEX : ₹4700+ Cr (19% of Revenue) (16% of Revenue) • >85% Growth CAPEX; Building diversified portfolio across technologies 6% 17% • Healthy order book, internal pipeline and key By Growth CAPEX API
Slide 8: Strengthening Integrated manufacturing network & Capabilities to enable customers
Strengthening Integrated manufacturing network & Capabilities to enable customers Small Molecules API & FDF R&D Fermentation CGT & ADC Unit 1 & 3, Vizag +3600 kL Unit 6, Vizag 1476 kL R&D 1 & Kilo lab, Hyderabad LB-1 & LB-2, Bangalore CAR-T unit-1, Mumbai +240 kL +600 treatment Unit 5, Vizag 161 kL
Slide 9: Confirming SBTi targets and consistent ESG recognition
Confirming SBTi targets and consistent ESG recognition Scope 1 + 2 Scope 3 • >50% electricity from renewable source (Wind+Solar) by 2031 via PPA for all sites SBTi roadmap Target Target towards GHG • Near term GHG reduction target -42% -51.6% validated by SBTi reduction target 2031 • Sustainable Pro
Slide 10: Financial Overview
2 Financial Overview Q1 - FY 2027 9
Slide 11: 1Q FY27: Highest Revenue, EBITDA and Profit momentum
1Q FY27: Highest Revenue, EBITDA and Profit momentum 1Q FY27 Financial Summary Comments [₹ Crore] 4Q FY26 1Q FY27 1Q FY26 Y-o-Y Q-o-Q • Revenue : ₹ 2,026 Cr, increased 29% primarily driven by robust CDMO growth supported by sustained Affordable Medicine business (led by FDF) Revenue 1,812 2,026 1,57
Slide 12: 1Q FY27: Driven by Solid CDMO performance
1Q FY27: Driven by Solid CDMO performance 1Q FY27 Divisional Revenue Performance 1Q FY27 Divisional Mix [₹ Crore] 4Q FY26 1Q FY27 1Q FY26 Y-o-Y Q-o-Q CDMO 589 870 522 67% 48% 25% Small molecules 524 835 493 69% 59% Affordable Bio 65 35 29 21% -46% 41% Medicines Affordable 57% ₹ 2,026 Cr CDMO 43% 1,2
Slide 13: Quarterly Performance Summary: Sustained growth momentum
Quarterly Performance Summary: Sustained growth momentum EBITDA & Gross Profit Margins Revenue [₹ Cr] 900 [₹ Cr] 62.7% GPM 800 59.4% 59.9% 60.9% 61.4% 60.0% 55.2% 56.9% 54.5% 2,026 31.8% OPM 700 50.0% 1,720 1,778 1,812 600 28.9% 1,653 27.7% 27.3% 1,570 40.0% 26.0% 500 1,415 24.8% 1,224 20.1% 400 30.
Slide 14: Business Review & Strategy
3 Business Review & Strategy Q1 - FY 2027 13
Slide 15: CDMO – Small molecules: High quality execution, Continuous capacity expansion
CDMO – Small molecules: High quality execution, Continuous capacity expansion Revenue Growth Comments [₹ Cr] Y-o-Y ▲ 69% • Strong business model driving continuous growth; +69% Y/Y, Q-o-Q ▲ 59% driven by steady progression of late-stage clinical projects and commercial API supplies 835 • Sustained b
Slide 16: Bio – Healthy demand and pipeline progress
Bio – Healthy demand and pipeline progress Revenue Growth Comments [₹ Cr] Y-o-Y ▲ 21% • Growth through revenue diversification continues; +21% Y/Y Q-o-Q ▼ 46% • Healthy pipeline progress on high potential larger Global accounts across AOF and CDMO 65 • Strong traction in the enzymatic technology app
Slide 17: Affordable Medicines – Sustained momentum amid macro volatility
Affordable Medicines – Sustained momentum amid macro volatility Revenue Growth Comments [₹ Cr] Y-o-Y ▲ 10% • Healthy order book, steady ARV and established product Q-o-Q ▼ 5% volume growth/new launches in US driving 10% growth 1327 • Consistent deliveries track record amid continuing global supply 1
Slide 18: Advanced Biologics – Key Updates
Advanced Biologics – Key Updates Gene Therapy & Anti body Drug Conjugates (ADC) Cell Therapy • In-licensed two ADC assets from Aarvik Therapeutics for • Continued uptake in volumes >660 infusions as on Jun 2026 development and commercialization for India markets • 2nd GMP production facility in Navi
Slide 19: Highest standard of Quality & Compliance - Commitment to “One Quality for all Markets”
Highest standard of Quality & Compliance - Commitment to “One Quality for all Markets” Last US FDA inspection 54 Successful Inspections by major Key Facilities Key Regulatory Certifications Date # audits (since inception) EIR Status Regulators (US FDA, WHO, EU EMA, and Japan PMDA) Kilo Lab – USFDA,
Slide 20: Earnings call details
Earnings call details Laurus Labs Results Conference Call to be held on Friday, 24 July 2026 at 5:00 PM IST Dial – In – Details Universal Dial-In +91 22 6280 1384 Click below to Express Join with India Local access Number +91 22 7115 8285 Diamond Pass Singapore +800 1012045 Click here to register Ho
Slide 21: Additional Information
Additional Information Laurus Labs is a research-driven pharmaceutical and biotechnology company committed to improving global health. It holds a leadership position in developing and manufacturing select Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF) across anti-retroviral